Incyte Corporation (NASDAQ:INCY) announced Friday that it will not proceed with the planned Phase 3 MAESTRA-3 clinical study evaluating its selective CDK2 inhibitor, INCB123667, in combination with bevacizumab as a first-line maintenance therapy for patients with ovarian cancer. The trial had been expected to begin in the fourth quarter of 2026.
According to a statement in the company’s press release, the decision was made as part of Incyte’s prioritization of its clinical development portfolio. The company stated that the determination was not based on any safety or efficacy findings from the INCB123667 clinical program.
Incyte also reported that it does not expect this decision to affect its financial guidance or its previously disclosed long-term outlook.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.